Sigvotatug vedotin for advanced solid tumors that spread
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Women’s health & pregnancy clinical trials.
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these cancers: non-small lung cancer, head and neck squamous cancer, HER2-negative breast cancer, esophageal squamous cancer, esophageal/GE-junction adenocarcinoma, skin squamous cancer, pancreatic adenocarcinoma, bladder cancer, cervical cancer, gastric cancer, or high-grade serous ovarian cancer.
- Your cancer is metastatic (spread) or cannot be removed by surgery.
- Your cancer can be measured on scans (the study calls this “measurable disease”).
- Your general strength is good (ECOG performance status 0 or 1).
- You can get a tumor biopsy (a fresh biopsy or a recent stored sample, depending on the study part).
- You’re not likely to have certain brain/nerve/lung complications or recent serious infections, as described in the study rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two medicines (sigvotatug vedotin and pembrolizumab) for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that has high levels of a protein called PD-L1. The treatment is designed to help your immune system fight the cancer more effectively, and this study aims to see how well it works.
This study tests a new medicine called PF-08634404 (an antibody-drug conjugate that targets cancer cells) combined with other anti-cancer drugs in people with advanced non-small cell lung cancer. It aims to see if these combinations are safe and effective. You may be eligible if your cancer has not responded to prior treatments or if you have not received any systemic treatment for advanced disease.
This trial tests whether adding the experimental drug becotatug vedotin to standard chemotherapy and radiation therapy can improve outcomes for patients with locally advanced esophageal squamous cell carcinoma. It may help shrink the tumor or slow its growth.
This trial tests a new drug combination for people with advanced stomach cancer that has not been treated before. It looks at two groups: one with PD-L1 (a protein that helps decide if immunotherapy works), and one without. The treatment includes an antibody-drug conjugate (Sonesitatug Vedotin) plus standard chemotherapy, with or without an immunotherapy drug.
This trial tests a new targeted drug (Becotatug Vedotin) given either alone or with an immunotherapy drug for people with advanced esophageal squamous cell cancer that has EGFR protein on their tumor cells. The goal is to see if this combination can help when standard treatments have stopped working.
This trial tests a combination of three drugs—becotatug vedotin, tislelizumab, and low-dose lenvatinib—for people with advanced esophageal cancer that has progressed after standard treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.